Passive Immunity: A Historical Perspective {#s0010}
==========================================

In 1890, Emil von Behring and Shibasaburo Kitasato, working in Robert Koch's laboratory in Berlin, Germany, initially reported that injections of toxin from diphtheria or tetanus bacilli led animals to produce in their blood substances capable of neutralizing the toxins. Furthermore, injections of blood serum from an animal that had been given a chance to develop antitoxins to tetanus or diphtheria could confer immunity to the disease on other animals and even cure animals that were already sick. From this, von Behring concluded that immunity was conferred by protective substances in the blood, which he called antitoxins, and that these substances were specific, protecting against only one particular disease ([@bib262]). In the same period in Robert Koch's laboratory, Paul Ehrlich showed that acquired immunity in mice can be transferred to the offspring from the mother by supplying antibodies to the fetus through the circulation and to the neonate through colostrum ([@bib224]). He was the first to use the term "Antikörper" in one of his articles and to define the differences between active and passive immunity.

On the suggestion of Koch, Behring and Ehrlich worked on the optimization of large-scale production of the diphtheria antitoxin for human use. Clinical tests with diphtheria serum in early 1894 were successful and in August the chemical company Hoechst started to market "Diphtheria remedy synthesized by Behring-Ehrlich." In 1904, Paul Ehrlich started developing the imaginative idea that it should be possible to find chemicals that target and kill disease-causing organisms while leaving normal body cells unharmed, which he named "magic bullets." He used the term first to describe an antibody and later, a chemical that binds to and specifically kills microbes or tumor cells. Von Behring won the first Nobel Prize in Physiology or Medicine in 1901 for his work on serum therapy, while Ehrlich received a Nobel Prize (together with Elie Metschnikoff) in 1908 for his "side-chain" theory, a chemical theory to explain the formation of antibodies by circulating cells. Their work led to the development of a theory of humoral immunity and opened the door for specific treatment of infections using antisera and antibodies.

Serum therapy was largely used at the beginning of the century but was abandoned owing to hypersensitivity reactions and the introduction of antibiotics in the 1940s. In the second half of the twentieth century, the inability to treat certain viral diseases and the development of antibiotic resistance in bacteria drove efforts to develop antibody preparations suitable for oral and systemic administration ([@bib30], [@bib74]). The development of hybridoma technology for the production of monoclonal antibodies (mAbs) provided the means to produce large amount of antibodies with one specificity and isotype ([@bib116]). Technological advances, such as chimerization and humanization of mAbs, DNA shuffling, and phage display technology led to the generation of antibodies or antibody fragments (scFv and Fab fragment) with improved efficiency and reduced immunogenicity ([@bib37]). New methods of production of antibodies were developed, including recombinant bacteria, insect cells, transgenic plants, and transgenic animals. The discovery of camelidae heavy chain antibody lacking light chains resulted in the development of single domain antibody fragments or nanobody technology ([@bib81]). Meanwhile, a new generation of receptor proteins derived from small and robust non-immunoglobulin "scaffolds" was born ([@bib17]).

Role of Antibodies in Protection Against Pathogens {#s0015}
==================================================

The vast majority of infectious agents invade the human body through the epithelial barrier of the gastrointestinal, genitourinary, and respiratory tracts. The mucosal immune system responds by producing large amount of immunoglobulins in mucosal secretions that act as a first line of defense against these pathogens. In humans, secretory IgA (SIgA) represents the most abundant immunoglobulin in body secretions such as saliva, tears, colostrum, and gastrointestinal; together with a variety of innate mucosal defense mechanisms, the function of secretory antibodies is to perform immune exclusion of exogenous antigens ([@bib22]). If the pathogens cross the epithelium and invade the body, locally produced antibodies will no longer determine the fate of the host and systemic immunity will take over. Serum immunoglobulin (particularly immunoglobulin \[Ig\]G) will then function as a second line of defense by eliminating pathogens that have breached the mucosal barrier. Patients with primary immunodeficiencies involving IgA are known to be highly susceptible to respiratory and gastrointestinal tract infections, which supports the notion of a crucial role for antibodies in the mucosal defense and suggests a useful role of passive immunity in the management of mucosal infections ([@bib257]).

Antibodies that bind to antigens may mediate various different biological effects ([@bib31]). In bacterial infections they can block adhesins, promote agglutination, neutralize enzyme activity and toxins, facilitate opsonization, and, together with complement, promote bacteriolysis; in viral disease, antibodies block viral entry into uninfected cells, promote antibody-directed cell-mediated cytotoxicity by natural killer cells, and neutralize virus directly or with the participation of complement.

Naturally Acquired Passive Immunity {#s0020}
===================================

Maternal passive immunity is a type of naturally acquired passive immunity and refers to antibody-mediated immunity. Transfer of maternal antibodies from mother to fetus or the newborn is essential for the development of the immune system and the protection of young animals from various pathogens in their early lives. The transfer of passive immunity from mother to young is a feature of most if not all orders of mammals. This generally occurs by transfer of maternal serum IgG from the mother to the offspring either in utero or after birth, by ingestion of immunoglobulin-rich colostrum by the neonate.

The pathways for transfer of passive immunity vary in different animals. Maternal IgG is transferred mainly through the placenta before birth in guinea pigs, rabbits, nonhuman primates, and humans, whereas in ruminant (sheep, cattle, and goats), horses, and pigs, newborns are born agammaglobulinemic and receive maternal antibodies exclusively through colostrum ([@bib142]). In rodents, cats, and dogs, maternal antibodies are transported to the offspring both antenatally and neonatally.

A pivotal molecule responsible for the transfer of maternal IgG in mammals is the neonatal Fc receptor (FcRn) (see also Chapter 20). Neonatal Fc receptor is a major histocompatibility complex class I-related molecule consisting of an α-chain and β2-microglobulin, and was first identified as the protein that mediated transfer of maternal, milk-born IgGs across the neonatal rodent intestine ([@bib73], [@bib108]). Further studies revealed a similar receptor in humans, where it was found to facilitate transport of maternal IgG to the growing fetus ([@bib130]). FcRn has since been identified in other mammals including nonhuman primates ([@bib227]) and ruminants such as sheep and cows ([@bib165], [@bib164]). Neonatal Fc receptor also mediates transport of IgG through multiple mucosal barriers and protects both IgG and albumin from intracellular catabolic degradation and thus extends their half-lives.

In birds, maternal IgY, the homolog of IgG, is transferred across the yolk sac to immunize chicks passively during gestation and early life. The chicken yolk sac IgY receptor (FcRY) is the ortholog of the mammalian phospholipase A2 receptor, a mannose receptor family member, rather than an FcRn or major histocompatibility complex homolog ([@bib260]).

Milk Antibodies {#s0025}
---------------

In humans, the main role of colostrum consumption is to provide protection for the gastrointestinal tract because the IgG required to provide systemic immunity is transferred across the placenta before birth. This probably explains the high proportion of SIgA (90%) and low proportion of IgG (2%) in human colostrum and milk. Immunoglobulin A antibodies in breast milk reflect antigenic stimulation of gut-associated lymphoid tissue and nasopharynx-associated lymphoid tissue such as the tonsils. Breast milk thus contains antibodies directed against infectious agents and other exogenous antigens in the mother's environment, which are those likely to be encountered by the infant. Human breast milk may contain SIgA antibodies against a variety of infectious agents such as *Vibrio cholera*, *Campylobacter jejuni*, *Escherichia coli* (ETEC), *Shigella*, *Salmonella*, and rotavirus that protect the infected child from developing diarrhea ([@bib129]).

In animals, the content of Igs in colostrum and milk highly depends on the species ([@bib98]). In ungulate species such as cattle, sheep, goats, and pigs, the young are born essentially agammaglobulinemic and rely entirely on uptake of colostral Igs, especially IgG, for systemic immune protection. Colostral IgG content in these species is typically greater than 75% of the total Ig content. The total amount of Igs may also differ between colostrum and milk and bovine colostrum contains levels of Igs much higher (several 100-fold) than ordinary bovine milk ([@bib98]). Immunoglobulins found in mammary secretions arise from systemic and local sources. In the case of IgG in milk, the major portion comes from the serum and enters via a selective receptor-mediated intracellular route through receptors (FcRn) on the surface of epithelial cells ([@bib163]). The uptake of milk-derived IgG by the intestine also varies between species. In rats and mice, there is FcRn-mediated uptake of IgG from the colostrum and milk in the neonate intestine. In newborn artiodactyls, all proteins (including IgG) are nonselectively absorbed in the first 12 h after birth and the ability of the enterocytes to pinocytically transport IgG is lost after 24 h ([@bib199]). Macromolecules so transported are released into the lamina propria and are then absorbed into the lymphatic or portal circulation.

Vaccination or natural immunization of the pregnant cow, ewe, or sow against enterotoxigenic *E. coli* or intestinal viruses can provide a degree of protection for the newborn ([@bib98]). In neonatal calves and piglets, maternal Ig is transferred into respiratory tract secretions and contributes to local protection against infections caused by viruses including bovine respiratory syncytial virus (RSV) or porcine respiratory coronavirus ([@bib14], [@bib217]).

These results on the transfer of antibodies have been crucial in understanding passive immunity against pathogens and developing passive immunotherapy in the management of such infections.

Artificial Induction of Passive Immunity {#s0030}
========================================

Advantages and Disadvantages {#s0035}
----------------------------

Unlike active immunity, which can take days or weeks to develop, passively administered antibodies have the ability to provide rapid and immediate protection: for example, against agents of bioterrorism ([@bib31]). Unlike vaccination, with which protective immunity depends on the host's ability to mount an immune response, passive antibody is independent of the recipient's immune status. Passive immunization may thus represent the therapy of choice in highly endemic areas where vaccine responses may be poor, or in selected groups of patients such as hospitalized individuals or those suffering from malnutrition and immunodeficiency, or in individuals in whom vaccination is contraindicated.

However, protection conferred by passive immunization is of short duration and might need repeated administration. Furthermore, when given at the mucosal surface, such as oral delivery, antibodies may be degraded by gastric acid and proteolytic enzymes. Production and purification of large amount of antibodies can thus result in high costs. Another disadvantage for mAbs is the emergence of variants that lack the determinant that the antibody recognizes, such as viral escape mutants. Recent research makes use of technologies for engineering more resistant antibodies that can react to multiple epitopes.

Source of Antibodies {#s0040}
--------------------

The choice of an antibody used for therapy against an infectious agent may depend on the route of administration, the status of the host, the microorganism that is targeted, or economic factors. Various antibody isotypes may confer different biological properties to the antibody molecules. Certain classes of Igs, such as IgA, appear to be more resistant to proteolytic degradation than other classes and therefore have some advantages for oral administration. Whereas eradication of an infection may require a full antibody to mediate phagocytosis, complement activation, or antibody-dependent cellular cytotoxicity, an antibody fragment may be sufficient for neutralization of a toxin or a virus. Immunoglobulin A or antibody fragments not interacting with the host immune system might also be more desirable for protection of mucosal surfaces to promote immune exclusion without inducing inflammation.

Furthermore, humanized mAbs are more appropriate for intravenous administration than a polyclonal antibody because they are less likely to transmit infectious diseases and cause toxicity. However, polyclonal antibody preparations are usually less costly to produce and may be a better choice for oral administration.

### Polyclonal Serum Antibodies {#s0045}

Protection against certain infections or a reduction in the severity of the illness they cause can be achieved by administering polyclonal antibodies derived from human or animal serum. The preparations available may be standard Ig of human origin, sometimes referred to as immune serum globulin or gammaglobulin, or special preparations of either human or animal sera containing high titers of specific antibodies to a particular microorganism or its toxin ([@bib186]). Products of human origin are preferred over those of animal origin because of the high incidence of adverse reactions to animal sera and the longer-lasting protection conferred by human Igs.

Immunoglobulin, often referred to as gammaglobulin, is produced by combining the IgG antibody fraction from thousands of adult donors. It is based on the assumption that a large pool will contain protective levels of antibodies of different specificities including antibodies against many common diseases such as hepatitis A, measles, and rubella. The Ig product is sterile and contains more than 95% purified IgG with small amounts of IgA and IgM. It is used primarily for post-exposure prophylaxis for hepatitis A, rubella, and measles and treatment of certain primary immunodeficiency disorders (X-linked α-gammaglobulinemia and hypogammaglobulinemia), secondary immunodeficiency (such as B-cell chronic lymphocytic leukemia), or autoimmune diseases. Historically, Igs were given subcutaneously or intramuscularly because the IgG preparations contained aggregated IgG and impurities that often caused serious reactions when administered intravenously. Today, intravenous Ig (IVIG) and subcutaneous Ig (SCIG) replacement therapy is generally accepted as treatment for selected patients with immunodeficiencies. Currently, the accepted therapy for IgG deficiency is the intravenous administration of 300--600 mg/kg IgG once every 3--4 weeks or 100--200 mg/kg/week subcutaneously ([@bib186]). Immunoglobulin therapy, given by both the intravenous and subcutaneous routes, is equally efficacious in infection reduction ([@bib72], [@bib41]) and decreases the frequency and severity of otitis and respiratory tract infection ([@bib229]).

Human hyperimmuneglobulins are made from the donated plasma of humans with high levels of the antibody of interest. Some preparations of Ig are harvested from selected individual donors who either recently recovered from the disease or have been deliberately immunized against it. Hyperimmuneglobulins are used for postexposure prophylaxis for several diseases, including hepatitis B, rabies, tetanus, cytomegalovirus, and varicella ([@bib229]). Heterologous hyperimmune serum is produced in animals, usually horses (equine), against toxins from *Clostridium botulinum*, *Clostridium tetani*, and *Corynebacterium diphtheriae* ([@bib31]). A problem with this product is serum sickness, an immune reaction to horse proteins.

### Polyclonal Antibodies from Cows and Chicken {#s0050}

There are a number of advantages to using cows and chickens for the production of antibodies. Bovine colostrum and IgY production are less invasive, requiring only the collection of eggs or milk compared with blood collection in mammals, and represent a relatively inexpensive source of antibodies.

Colostrum from immunized animals may have more than a 100-fold increase in antibody titers compared with colostrum from nonimmunized animals ([@bib109]). Colostrum contains between 30 and 200 mg of immunoglobulin per milliliter, most (75%) of which is IgG1 ([@bib16]). The cow produces about 1--1.5 kg of immunoglobulins in the first few days after calving; it is thus attractive for large-scale antibody production. Immunization protocols vary and generally, repeated immunizations are administered during late pregnancy or during the dry period. Many of these studies have used intramuscular or subcutaneous immunization, although some also have incorporated oral or intramammary immunizations but with less success. Mammary secretions are then collected either at the first milking or are pooled from the first four to six milkings or from the first six to 10 days after calving ([@bib98]).

Immunization of chickens requires only small amounts of antigens to obtain high and long-lasting IgY titers in the egg yolk ([@bib240]). The most common injection route is intramuscular because it results in higher levels of specific IgY antibodies than subcutaneous immunization ([@bib39]). The concentration of IgY in egg yolk can reach 25 mg/mL. Because a hen can lay up to 250 eggs in a year, the yield of hyperimmunized IgY could be large. Because 160 mg of IgY could be obtained from a single egg, one immunized hen could produce 40 g of IgY in a year, of which 1--10% can be expected to be antigen-specific ([@bib84]). In contrast to mammalian serum, egg yolk contains only a single class of antibody (IgY), which can easily be isolated from the yolk by precipitation techniques, and IgY does not activate mammalian complement or interact with mammalian Fc receptors that could mediate an inflammatory response ([@bib118]).

The resistance of bovine IgG1 and IgY to low pH and luminal proteolysis makes them functionally similar to human IgA and suitable for oral administration ([@bib118]). Ruminants transmit maternal immunity only postnatally through colostral antibodies ([@bib199]), so colostrum and egg yolk antibodies are routinely used for prophylaxis and therapy of infectious diseases in farm animals ([@bib16]). Bovine immunoglobulin preparations against rotavirus and *E. coli* ETEC have been commercially available for use in farm animals for decades owing to their low cost and easy administration.

A high number of controlled clinical studies using hyperimmune bovine colostrum or egg yolk antibodies have shown both prophylactic and therapeutic effects against oral and gastrointestinal pathogens in humans, including enterotoxicogenic *E. coli*, *Helicobacter pylori*, the dental caries causing *Streptococcus mutans*, and rotaviral infections ([@bib98], [@bib118], [@bib257]). The ability of bovine and egg yolk antibodies to provide protection against a specific disease continues to be an area of interest ([@bib178]). For example, bovine IgG with gp140 reactivity and able to neutralize human immunodeficiency virus (HIV) has been developed as a potentially efficacious and affordable topical microbicide ([@bib119]).

### Monoclonal Antibodies by Hybridoma Technology {#s0055}

The first generation of mAb was produced by a single hybridoma clone obtained by the fusion of a myeloma cell with plasma cells from an immunized mouse. The use of therapeutic mAbs of animal origin was compromised by immunologic responses to the mAbs themselves. The creation of chimeric mAbs composed of human constant domains (C~H~ and C~L~) and rodent variable domains (V~H~ and V~L~) led to a reduction of human anti-chimeric antibody response. Humanization of mAbs consisting of CDRs of a rodent mAb cloned into the framework regions of a human mAb reduced the immunogenicity further, but not as much as expected ([@bib37]). Furthermore, humanization is often accompanied by a loss in affinity and some residues in the framework regions need to be back-mutated to achieve acceptable affinity.

To circumvent the immunogenicity issue, full human mAbs can be generated from transgenic mice ([@bib37], [@bib137]). This relies on the generation of transgenic mice in which the murine immunoglobulin genes have been disrupted and replaced with human Ig gene clusters. The transgenic mice produce human antibodies in response to immunization with an antigen and the clone can be isolated through hybridoma technology or phage antibody libraries.

Nearly 30 therapeutic mAbs have been approved by the Food and Drug Administration for marketing in the United States today ([@bib273]). Most of them originated from hybridomas and are in the full-length antibody molecular format, including the murine, chimeric, humanized, and human antibody category. Only one mAb, palivizumab (humanized mAb), has been licensed for an infectious disease (*respiratory syncytial virus* infection) ([@bib27], [@bib95]). Monoclonal Abs against HIV, viral hepatitis, rabies, *Clostridium difficile* toxins, and *Pseudomonas aeruginosa* are under clinical development ([@bib27], [@bib176]). Raxibacumab, a human mAb against the protective antigen (PA) of *Bacillus anthracis*, significantly increased survival in monkeys (64% vs 0% for placebo) after inhalation of anthrax spores ([@bib169]). The license, resubmitted in 2012, contains additional validation of previous data and evaluation of potential added benefit of using raxibacumab with antibiotics versus antibiotics alone.

### Recombinant Antibodies Using Phage Display {#s0060}

Limitations in hybridoma technology and advances in molecular biology led several research groups to investigate the production of antibody in a recombinant form. Because the full antibody cannot be easily expressed in bacteria owing to impaired folding, a technology in which only antigen-binding parts of the antibody molecule (Fab or Fv fragments) are expressed in *E. coli* has been introduced ([@bib225]). It was later shown that an scFv fragment can be displayed on the phage surfaces as a functional protein that retains an active antigen-binding domain capability ([@bib65]). In the past decade, the phage display technique has been routinely used for generation and selection of scFv, Fab, and single V~L~ or V~H~ domain derived from conventional antibodies and variable domain of camelidae heavy chain antibodies (VHH) ([Figure 1](#f0010){ref-type="fig"} ). There is growing interest in producing new formats of antibodies to be tailored as desired and produced in large quantities, employing bacterial and yeast cultures.Figure 1Schematic representation of antibodies and antibody fragments.The conventional antibody contains two variable regions (each composed of V~H~ and V~L~ domains) that confer antigen-binding specificity of antibody and an Fc fragment in the constant region that recruits effecter functions of the immune system. Camelidae heavy chain antibodies lack both constant and variable light chains (C~L~ and V~L~) and the first heavy chain constant (C~H~1) domain, and the antigen-binding site is formed only by the heavy chain variable domain (V~H~H or nanobody).

#### Antibody Fragments Derived from Conventional Antibodies (scFv, Fab, V~H~, and V~L~) {#s0065}

A single chain fragment variable (scFv) is about 30 kDa and consists of variable regions of heavy (V~H~) and light (V~L~) chains that are joined together by a flexible peptide linker. In the scFv, the order of the domains can be either V~H~-linker-V~L~ or V~L~-linker-V~H~ and in both orientations. The peptide linker is usually a 15-aa linker with the sequence (Gly~4~Ser)~3~ ([@bib65]). The larger Fab is a heterodimer consisting of the variable and first constant domains of heavy (V~H~-C~H~) and light chain (V~L~-C~L~) segments linked by disulfide bonds. These fragments show similar binding specificities as the original antibodies and a low degree of immunogenicity and are more easily manipulated than the bivalent parent antibody. The smaller size of the fragments permits penetration into tissues inaccessible to full-size mAbs ([@bib268]). On the downside, fragments demonstrate short circulating half-lives in humans, most likely owing to kidney clearance. The Fab or Fv fragments can be successfully generated from hybridoma cells ([@bib121]). However, to select antibody fragments with different specificities and a high binding affinity, it is generally preferable to select the fragments directly from a phage library.

The selected scFv, Fab, V~H~, or V~L~ can be directly used as fragments or reconverted into different antibody formats such as full-length antibodies, scFv-CH3 (minibody), scFv-Fc, or diabodies, among others ([@bib88], [@bib176]) ([Figure 1](#f0010){ref-type="fig"}). The phage display technology has been used to generate at least 35 full-length human antibodies that are in clinical development, including CR6261 (influenza virus) and KB001 (*Ps. aeruginosa*) ([@bib176]).

#### Camilidae VHH Antibody {#s0070}

Members of the Camelidae family (i.e., *Camelus dromedarius*, *Camelus bactrianus*, *Lama glama*, *Lama guanaco*, *Lama alpaca*, and *Lama vicugna*) produce heavy chain-only antibodies (HCAbs), a type of antibody that lacks the first constant domain (Chapter 1) and light chains ([@bib81], [@bib202]). The antigen-binding fragments of such HCAbs are composed in a single-domain, referred to as VHH (variable domain of llama heavy chain antibodies) or nanobody. Camelidae heavy chain antibodies are small (12--15 kDa), stable molecules with superior solubility and similar affinities as conventional antibodies ([@bib83]).

Camelidae heavy chain antibodies exhibit several advantages over conventional antibodies and derived fragments because they are markedly more acid- and heat-resistant than conventional antibodies, and because they are formed by a single polypeptide, they are easier to express in a functional recombinant form ([@bib83], [@bib248]). These properties make them suitable for therapy at mucosal sites such as the gastrointestinal tract, where the acidic pH can limit the functionality of conventional antibodies. In addition, owing to their small size and naturally longer CDR3 regions, llama VHH antibody fragments are superior to conventional antibodies at accessing clefts such as active sites of enzymes and canyons on virus capsids ([@bib128]). Their small size also allows them to penetrate tissues and tumors more rapidly and deeply than mAbs. Camelidae heavy chain antibodies have low immunogenicity and are unlikely to exhibit untoward side effects during chronic application ([@bib44]). Moreover, camel milk contains heavy chain antibodies and is regularly consumed in African/Arabic countries without adverse effects.

Camelidae heavy chain antibodies are usually generated by polymerase chain reaction cloning of the variable domain repertoire from blood, lymph nodes, or spleen cDNA obtained from immunized animals into a phage display vector. Large-scale production of VHH in the yeast *Saccharomyces cerevisiae* is highly efficient and results in the secretion of functional antibody fragments (VHH) in the growth medium ([@bib69]). Several VHH are currently being studied for use in various areas, including infectious diseases ([@bib83]). Camelidae heavy chain antibodies have been generated against protozoa (*Trypanosoma evansi*), bacteria (*Str. mutans*, *Cl. difficile*, and *Cl. botulinum*), and viruses (respiratory syncytial virus, rotavirus, rabies virus, influenza, and HIV) ([@bib202], [@bib248]). Camelidae heavy chain antibodies against RSV and rotavirus are in clinical development ([@bib248]). Oral consumption of VHH against rotavirus has also been confirmed to be safe in human safety studies ([@bib280]).

The small size (gene and domain) and the strict monomeric and soluble behavior render VHH ideal to generate multivalent or multispecific constructs, or for integration in more complex assemblies by fusing to an Fc, an enzyme, or a toxin ([@bib248]). Bivalent or bispecific VHH constructs can be assembled to target multiple antigens or epitopes on the same cell or antigen, greatly improving neutralization potencies and reducing the risk of escape mutants ([@bib96]).

### Engineered Protein Scaffolds {#s0075}

With the emergence of protein engineering techniques, new binding proteins based on alternative scaffolds have been designed as therapeutic agents. New scaffold proteins should have more attractive physical and chemical properties than conventional antibodies such as higher solubility, affinity, and stability, or an absence of disulfide bridges for optimal expression in microorganisms. The diversity of potential applications has led to the investigation of more than 40 scaffolds including affibodies, fibronectins, DARPins, and variable lymphocyte receptors (VLR) of lamprey, among others ([@bib3], [@bib19], [@bib77], [@bib184], [@bib235]). To confer effector functions on these proteins, one can also fuse these scaffolds to the Fc region of antibodies. Several alternative binding proteins are now under preclinical investigation, but few data exist on the serum half-life, tissue penetration, or immunogenicity of most alternative binding molecules.

Production System for Recombinant Antibodies {#s0080}
============================================

Several expression systems are available for the production of antibodies and antibody fragments, including bacteria, yeast, plant, insect, and mammalian cells as well as transgenic animals ([@bib215]). Mammalian cell cultures, predominantly Chinese hamster ovary cells and the murine myeloma cell line NSO, are the dominant production platforms for therapeutic mAb whereas yeast is generally used for VHH fragments.

There is a need to develop technology to produce antibodies at lower costs. Although tobacco was used in the early studies ([@bib87]), a large number of different crops can now be used to produce antibodies and antibody fragments, including cereals, legumes, and fruits ([@bib215]) (see also Chapter 66). Plantibodies to combat infectious diseases include SIgA that recognizes the surface antigen I/II of *Str. mutans* for protection against caries produced in tobacco, a humanized anti-CCR5 antibody (Mapp66) produced in tobacco and an anti-gp120 human mAb produced in maize for use as a topical microbicide to prevent HIV infection, and a VHH fragment against rotavirus produced in rice (Mucorice-ARP1) ([@bib241], [@bib272]). Plant bioreactors are expected to yield over 10 kg of therapeutic antibody per acre of tobacco, maize, soybean, and alfalfa and costs at least 10 times less compared with steel-tank bioreactors using mammalian cells or microorganisms ([@bib127]). Antibody-containing cereal such as rice, wheat, and pea seeds can be stored at room temperature, a major advantage for use in developing countries.

The use of transgenic farm animals for production of mAbs in milk and egg yolk was investigated previously ([@bib36], [@bib53], [@bib93], [@bib112], [@bib132], [@bib194], [@bib275]). The advantages of transgenic animals for antibody production would be the low cost production as well as the high quality of the proteins. Farm animals could also be used for the production of polyclonal human antibodies ([@bib92]). Transgenic cattle have been generated by transferring a human artificial chromosome vector carrying the entire unrearranged, human Ig heavy (hIGH) and κ-light (hIGK) chain loci to bovine fibroblasts in which two endogenous bovine IgH chain loci were inactivated ([@bib125]). The production of only human antibodies awaits for the complete inactivation of the corresponding cow Ig genes. A similar approach is also currently being performed in chickens ([@bib92]).

Lactobacilli are gram-positive bacteria that are normal residents of the oro-gastrointestinal and vaginal tract and are also used in food fermentation and preservation. Their generally regarded as safe for humans status has led to reports in which lactobacilli producing antibody fragments (i.e., lactobodies), either secreted or displayed on their surface, are directly used for oral administration and treatment of mucosal infections ([@bib276], [@bib121], [@bib123], [@bib153], [@bib158], [@bib189]). Stable and contained expression systems have been developed allowing transformed lactobacilli to be administered to humans ([@bib158]). The antibody fragment can be expressed in lactobacilli isolated from the oral, gastrointestinal, or vaginal tract to protect different mucosal surfaces. The use of genetically engineered antibody fragments produced and locally delivered by bacteria in the mucosal sites could thus provide an efficient therapy at low cost, particularly in developing countries.

Passive Administration of Antibodies {#s0085}
====================================

Passive immunization has been used for more than 100 years against various pathogens in both animals and humans. We will summarize published data on the use of antibodies for prophylaxis and therapy against selected pathogens that infect the oral, pulmonary, gastrointestinal, and vaginal tracts ([Table 1](#t0010){ref-type="table"}, [Table 2](#t0015){ref-type="table"}, [Table 3](#t0020){ref-type="table"}, [Table 4](#t0025){ref-type="table"} ). We also want to highlight the protection conferred by different forms of antibodies that are being developed, produced, and delivered using different approaches and technologies.Table 1Passive Immunization Against Oral PathogensPathogenAntibody SourceTargeted AntigenSubjectAdministrationOutcomeReferences*Streptococcus mutans*Cow milk*Str. mutans*RatDiet supplemented with immune milkDecrease in caries and count of *Str. mutans* in dental plaque[@bib167]Cow milk*Str. mutans*HumanDaily mouth rinse with immune milkReduced counts of *Str. mutans* in dental plaques[@bib64], [@bib135]IgY*Str. mutans* or GtfsRatDiet supplemented with IgYInhibition of dental plaque accumulation and caries development[@bib79], [@bib124], [@bib187]IgY*Str. mutans*HumanDaily mouth rinse containing IgYDecreased number of *Str. mutans* in the saliva of healthy volunteers[@bib84]Murine mAbAgI/IIRhesus monkeyRepeated topical application of mAbs (Guy's 13, IgG1) onto teethPrevented colonization by *Str. mutans* and caries development over a period of 1 year[@bib131]Murine mAbAgI/IIHumanTopical application (3 times) of mAbs Guy's 13 onto teethReduced the colonization of exogenously applied *Str. mutans*[@bib148]Murine mAbAgI/IIHumanTopical application (6 times) of mAbs Guy's 13 onto teethPrevented the recolonization of resident *Str. mutans* for up to 2 years[@bib147], [@bib146]Plant-SIgA/GAgI/IIHumanTopical application (6 times) of SIgA/G (CaroRx™) onto teethPrevented the recolonization of resident *Str. mutans* for up to ^4^months[@bib144], [@bib145]Lactobacilli- scFvAgI/IIRatRepeated topical application of lactobacilli-scFv anchored in the oral cavityReduced *Str. mutans* counts and caries scores[@bib121], [@bib123]VHHAgI/IIRatOrally daily pipetting of VHH (S-36)Reduced development of caries[@bib122]*Porphyromonas gingivalis*IgYGingipainsHumanSingle subgingival application of IgY gelPrevented recolonization by *Po. gingivalis* for a period of 4 weeks[@bib270]Mouse mAbGingipain RgpAHumanSubgingival application (4 times) of mAb 61BG1.3 (IgG1)Prevented recolonization of deep pocket with *Po. gingivalis* for up to 9 months[@bib20]*Candida albicans*IgY*Candida*MouseDaily oral application of a IgY gelReduced oral candidiasis and systemic dissemination in immunosuppressed mice[@bib102]Bovine colostrum*Candida* + mannanHumanDaily oral administration of bovine antibodies in a chocolate drinkReduction in *Candida* count in saliva of bone marrow--transplanted patients[@bib242]Human scFvhsp90MouseSingle intravenous dose of efungumab (Mycograb^®^) in combination with amphotericin BCombination more efficient than amphotericin B only in killing *Can. albicans*[@bib162]Human scFvhsp90HumanIntravenous doses of efungumab (Mycograb^®^) (1 mg/kg) for 5 days in combination with amphotericin BCombination more efficient than amphotericin B only in patients with invasive candidiasis[@bib188]Table 2Passive Immunization Against Lung PathogensPathogensAntibody SourceAntigenModelAdministrationOutcomeReferencesVarious lung infectionsHuman purified IgHumanIVIG and SCIGReduced incidence of pneumonia in patients with PAD[@bib41], [@bib70], [@bib263]*Haemophilus influenzae* HibHuman hyperimmune globulinPolysaccharideHuman (infants)Intramuscular administration of IgProtection against Hib bacteremia and meningitis in infants[@bib210], [@bib223]Human hyperimmune globulinPolysaccharideHuman (infants)Intramuscular administration of IgDecreased the frequency of acute otitis media in infants[@bib222]*Streptococcus pneumoniae*Human mAbCapsular polysaccharideMouseIntraperitoneal administration of mAb A7 (IgM)Protective against a systemic lethal challenge with *Str. pneumoniae* serotype 3[@bib40], [@bib61], [@bib60]Murine mAbCapsular polysaccharideMouseSingle intraperitoneal dose of mouse mAbs (IgG1)Prophylactically protective against a lethal intranasal challenge with *Str. pneumoniae* serotype 3[@bib239], [@bib256]*Pseudomonas aeruginosa*Human mAb derived from scFvExopolysaccharide PslMouseSingle intraperitoneal dose of mAb Cam-003 (IgG1)Prophylactically protective in a lethal *Ps. aeruginosa* pneumonia mouse model[@bib55]Human mAbAlginateMouseSingle intranasal administration of mAb (IgG1)Prophylactically protective in a lethal *Ps. aeruginosa* pneumonia mouse model[@bib193]Human mAbFlagellin type bMouseSingle intravenous injection of mAb LST-007 (IgG1)Therapeutically protective in a lethal *Ps. aeruginosa* pneumonia mouse model[@bib1]Human mAbType 3 secretion system (PcrV)MouseSingle intravenous injection of mAb KBPA101 (IgM)Prophylactically protective in a lethal *Ps. aeruginosa* pneumonia mouse model[@bib90]Human FabType 3 secretion system (PcrV)MouseIntratracheal administration of Fab fragments (IA8)Protective in a lethal *Ps. aeruginosa* pneumonia mouse model[@bib12]Human mAbLPS O- polysaccharide moietyHumanThree infusion of panobacumab (IgM) (1.2 mg/kg)High rate of clinical cure and survival in patients developing nosocomial *Ps. aeruginosa* O11 pneumonia[@bib141]Human PEGylated Fab'Type 3 secretion system (PcrV)HumanSingle intravenous infusion of mAb KB001 (3 mg/kg)Reduction in *Ps. aeruginosa* pneumonia incidence in mechanically ventilated patients[@bib67]IgY*Ps. aeruginosa*HumanMouth rinse containing IgY twice daily on a continuous basisReduction or prevention of *Ps. aeruginosa* colonization[@bib181]H5N1Human plasmaA/H5N1HumanTransfusion with plasma from humans recovering from H5N1 infectionRecovery from H5N1 influenza A viral infection in two case studies[@bib117], [@bib274]F(ab')2 (equine)A/H5N1MouseSingle intraperitoneal injection of F(ab')2Therapeutically protective against a lethal dose of H5N1[@bib140]IgYA/H1N1MouseSingle intranasal administration of IgYProphylactically and therapeutically protective against a lethal dose of H1N1[@bib179]Bovine IgG and F(ab')2A/H1N1MouseSingle intranasal administration of IgG or F(ab')2IgG prophylactically protected mice from a sublethal H1N1 dose more efficiently than F(ab')2[@bib178]Humanized mAbsHA (H5)MouseIntraperitoneal administration of mAbsProphylactically and therapeutically protective against a lethal infection with H5N1[@bib196], [@bib197]Murine mAbHA (H5)MouseSingle intranasal administration of mAb DPJY01 (IgA)Prophylactically and therapeutically protective against a sublethal dose of H5N1[@bib267]Human mAbHA (H1)MouseSingle systemic injection of mAb 6F12 (IgG2b)Prophylactically and therapeutically protective against a lethal challenge with H1N1[@bib233]Human mAbHA (H1, H2, H5, H6, H8, H9)MouseSingle systemic injection of mAb CR6261(IgG1)Prophylactically and therapeutically protective against a lethal challenge with H1N1 and H5N1[@bib57], [@bib238]VHHHA (H5)MouseSingle intranasal administration of mono- and bivalent VHHBivalent VHH prophylactically and therapeutically more protective against lethal infection with H5N1[@bib101]RSVHyperimmune human IgGRSVRatsSingle intraperitoneal injection of IgGProphylactically and therapeutically protective against an intranasal challenge with RSV[@bib198]Human polyclonalRSVHuman (infants)Intravenous injection of RSV-IVIGReduced incidence of RSV hospitalization among high-risk infants and children by 30--60%[@bib172]Humanized mAbF GlycoproteinHuman (infants)Intramuscular injection Palivizumab (Synagis^®^) (IgG1)Reduced incidence of RSV hospitalization among high-risk infants and children by 30--60%[@bib172]Humanized mAbF GlycoproteinHumanIntramuscular injection Palivizumab (Synagis^®^)Prophylactically protected hematopoietic stem cell transplant patients from RSV infection[@bib111]VHHF GlycoproteinRatsIntranasal administration of trimeric (identical) VHHs (ALX-0171)Prophylactically and therapeutically protective against intranasal challenge with RSV[www.ablynx.com](http://www.ablynx.com){#interref1}VHHF GlycoproteinHumanTrimeric VHHs (ALX-0171) administered to volunteers via nebulizationNo adverse events in a phase I study[www.ablynx.com](http://www.ablynx.com){#interref2}Table 3Passive Immunization Against Gastrointestinal PathogensPathogensAntibody SourceAntigenModelAdministrationOutcomeReferences*Helicobacter pylori*Monoclonal (mouse)*H. pylori* cells or ureaseMouseOral administration of mAbs at the time of the initial challengeProtected mice from *H. pylori* infection[@bib18], [@bib48]Bovine colostrum*H. pylori*HumanOral administration of immune colostrum daily for 28 daysInfection eradicated in all 11 patients[@bib5]Bovine colostrum*H. pylori*HumanOral administration of immune colostrum daily for 28 daysAttenuation of symptoms and decreased in *H. pylori* counts in most patients[@bib234]Bovine colostrum*H. pylori*HumanOral administration of HBC daily for 28 daysEradication of infection in two of eight patients[@bib33]Bovine colostrum*H. pylori*, urease or adhesinHumanOral administration of BIC for 2 days (4--8 g)No eradication of *H. pylori*[@bib185]Bovine colostrum*H. pylori*Human (infants)Oral administration of HBC daily for 30 daysNo decrease in *H. pylori* infection in infants in rural Bangladesh[@bib34]Bovine colostrum*H. pylori*Human (children)Oral administration of BIC daily for 28 daysNo decrease in *H. pylori* infection[@bib54]IgY*H. pylori* or ureaseGerbilsOral administration of IgYAttenuation of *H. pylori* colonization and gastric mucosal inflammation[@bib182], [@bib220], [@bib221]IgYUreaseMouseOral administration of IgYReduction in *H. pylori* colonization and inflammation in the stomach[@bib152]IgYUreaseHumanOral administration of IgY 3 times daily for 4 weeksDecrease in urea breath test values[@bib231]IgYUreaseHumanFunctional drinking yogurt containing 1% IgY 3 times daily for 4 weeksDecreased urea breath test values and reduced *H. pylori* antigen detection in feces[@bib89]RotavirusMouse mAbsVP4, VP6, VP7MouseSubcutaneous injection of hybridoma producing IgG and IgA mAbsProphylactically protective in the murine hybridoma backpack tumor model[@bib26], [@bib207]Bovine colostrumG1-G4 serotypesMouseOral administration of HBCProphylactically decreased diarrhea and reduced viral load in mouse pups challenged with rotavirus[@bib190]Bovine colostrumG1-G4 serotypesHuman (children)Oral administration of HBC for 14 daysProphylactically protected children admitted to hospital against rotavirus infection[@bib50]Bovine colostrumG1-G4 serotypesHuman (children)Oral administration of 10 g HBC for 4 daysTherapeutically reduced total stool output and frequency[@bib212]IgYG1-G4 serotypesMouseOral administration of IgYTherapeutically reduced prevalence and duration of diarrhea in mouse pups challenged with rotavirus[@bib213]IgYG1-G4 serotypesHuman (children)Oral administration of 10 g IgY for 4 daysTherapeutically reduce stool output[@bib211]VHHVP6 (various serotypes)MouseOral administration of VHHsVHH fragment 2B10 (or ARP1) reduced morbidity of rotavirus-induced diarrhea[@bib246]VHHVP6 (various serotypes)Human (children)Oral administration of VHH ARP1Therapeutically reduced severity in phase II clinical trial conducted in Bangladesh[@bib280]Lactobacilli-VHHVP6 (various serotypes)MouseOral administration of *Lactobacillus* expressing surface-anchored VHH against rotavirus (ARP1 and ARP3)Prophylactically and therapeutically decreased diarrhea and viral load in mouse pups challenged with rotavirus[@bib189], [@bib191], [@bib158]Plant-VHHVP6 (various serotypes)MouseOral administration of rice-produced ARP1 (Mucorice-ARP1)Prophylactically and therapeutically decreased diarrhea and viral load in mouse pups challenged with rotavirus[@bib241]*Clostridium difficile*Human polyclonal (IVIG)Toxin A and BHumanIntravenous infusion of human IgResolution of diarrhea, abdominal tenderness, and distention in patients with severe pseudomembranous colitis[@bib209], [@bib261]Human polyclonal (IVIG)Toxin A and BHumanIntravenous infusion of human IgThree of five cases with recurrent *Cl. difficile* infections responded successfully[@bib209]Human and humanized mAbsToxin A and BHamsterIntraperitoneal injection of mAbs CDA1 and CDB1Prophylactically and therapeutically prevented mortality in hamsters challenged with *Cl. difficile* spores[@bib10], [@bib156]Human mAbToxin A and BHumanSingle intravenous infusion of mAbs CDA1 (actoxumab) and CDB1 (bezlotoxumab) (10 mg/kg)Reduced rate of recurrent infection as adjunct to treatment with either vancomycin or metronidazole[@bib139]IgYToxin A and BHamsterDaily oral administration of IgYProphylactically and therapeutically prevented mortality in hamsters challenged with *Cl. difficile* spores[@bib115]IgYFliDHamsterDaily oral administration of IgYTherapeutically prevent mortality in hamsters challenged with *Cl. difficile* spores[@bib175]Bovine colostrumToxin A and BHamsterDaily oral administration of BICProphylactically prevented mortality in hamsters challenged with *Cl. difficile* spores[@bib143]Bovine colostrum*Cl. difficile* + toxin A and BHumanOral administration of BIC for 2 weeks (10 g/day) after antibiotic therapyNone of the patients had another episode of *Cl. difficile* diarrhea[@bib183]Bovine colostrum*Cl. difficile* + toxin A and BHumanOral administration of BIC for 2 weeks (5 g/day) after antibiotic therapyReduction of relapse rate compared with contemporary controls[@bib247]Lactobacilli-VHHToxin BHamsterDaily oral administration of lactobacilli expressing surface-anchored VHHDelayed the death of hamsters after challenge with spores from toxin A-deleted *Cl. difficile* strainAndersen et al. (submitted)*Escherichia coli*Human mAbStx2 of\
EHECPigletSingle intraperitoneal injection of human mAbs against Stx2Protected against systemic complication after onset of diarrhea[@bib173], [@bib219]IgYStx2 of\
EHECMouseOral administration of anti-Stx-2 IgYTherapeutically reduced mortality of mice infected intestinally with EHEC O157:H7[@bib177]IgYFimbrial antigen of ETECPigletDiet containing IgY for period of 8 daysReduce incidence and severity of diarrhea[@bib157]IgYPilus of ETECCalfFed milk containing IgYProphylactically protected neonatal calves from challenged with ETEC (K99+)[@bib103]Cow milkEPEC strainsHuman (infants)Oral administration of milk Ig concentrate for 10 days (1 g/kg/day)Therapeutically protective against EPEC-induced diarrhea in hospitalized infants[@bib168]Bovine colostrumETEC colonization factorHumanOral administration of HBC 3 times daily for 2 daysProphylactically protected against oral experimental challenge with ETEC (O78:H11)[@bib68]Bovine colostrumETEC and EPEC strainsHuman (children)Oral administration of HBC for 4 days (20 g/day)No therapeutic benefit against *E. coli*-induced diarrhea[@bib35]Bovine colostrumETEC strainsHumanTablets containing 400 mg HBC, 2 times daily for 7 daysProtected volunteers against ETEC-induced diarrhea[@bib279][^1]Table 4Passive Immunization Against Vaginal PathogensPathogensAntibody SourceAntigenModelAdministrationOutcomeReferencesSHIVHuman mAbsgp120 or gp41MonkeyIntravenous infusion of mAbs (b12, 2G12, 2F5, 4E10)Prophylactically protective in macaques vaginally challenged with SHIV[@bib85], [@bib86], [@bib192], [@bib160], [@bib277]Human mAbgp120MonkeyVaginally administered mAbsProphylactically protected 9 of 12 macaques vaginally challenged with SHIV[@bib249]HIVHuman mAbgp120 or gp41Mouse (RAG-hu)Intravaginal application of VRC01 or mix of b12, 2F5, 4E10, and 2G12 mAbsProphylactically protective in RAG-hu mice challenged vaginally with HIV-1[@bib251]Human mAbgp120 or gp41HumanInfusions of 2G12, 2F5, and 4E10Delay in viral rebound in chronically HIV-1 patients off ART[@bib245]Humanized mAbCD4HumanInfusions of mAb ibalizumabReductions in HIV-1 RNA levels in 20 of 22 HIV-1 patients off ART[@bib23]Humanized mAbCCR-5HumanSingle intravenous infusions of anti-CCR5 PRO 140 (5--10 mg/kg)Reduction in the viral load in 31 subjects infected with CCR5-tropic (R5) HIV-1[@bib106]Lactobacilli- scFvICAM-1Mice (SCID)Intravaginal administration of lactobacilli secreting scFvReduced transmission of cell-associated HIV in Hu-PBL-SCID mouse model[@bib38]*Candida albicans*Mouse mAbMP65 or Sap-2RatIntravaginal administration of mAbs AF1 (IgM) or GF1 (IgG1)Therapeutically protective against vaginal challenge with *Can. albicans*[@bib52]Human VH and VκMP65 or Sap-2RatIntravaginal administration of mono- or bispecific domain antibodiesProphylactically and therapeutically protective against *Can. albicans* infection equivalent to treatment with fluconazole[@bib51]Monoclonal (mouse)β-glucanRatIntravaginal administration of mAb 2G8 (IgG2b)Prophylactically and therapeutically protective against *Can. albicans*[@bib243]Plant-chimeric mAb and plant-scFv-Fcβ-glucanRatIntravaginal administration of two chimeric antibody (complete IgG or scFv-Fc) derivatives of mAb 2G8Therapeutically protective in vaginal rat model of *Cl. difficile* infection[@bib29]mAb and scFv anti-idiotypicIdiotype of anti-killer toxin mAbRatIntravaginal administration of mAb K10 and scFv-H6 fragments (yeast killer like-toxin)Therapeutically protective in vaginal rat model of *Cl. difficile* infection[@bib150]*Streptococcus gordonii*-scFv anti-idiotypicIdiotype of anti-killer toxin mAbRatIntravaginal inoculation of *Str. gordonii* expressing secreted or surface-anchored scFv-H6Therapeutically protective in vaginal rat model of *Cl. difficile* infection[@bib15][^2]

Oral Pathogens {#s0090}
--------------

### Streptococcus mutans {#s0095}

*Streptococcus mutans* is a normal resident of the human oral cavity recognized as one of the major etiologic agents of caries. Passive immunization against caries was developed using oral administration of antibody preparation against whole cells of *Str. mutans* or associated virulence factors involved in bacteria adherence ([Table 1](#t0010){ref-type="table"}). Oral administration of hyperimmune bovine milk or chicken antibodies against *Str. mutans* and glucosyltransferases resulted in a reduction in *Str. mutans* in dental plaque and caries formation in rats and reduced counts of *Str. mutans* in saliva or dental plaque in humans ([@bib64], [@bib79], [@bib84], [@bib124], [@bib135], [@bib167], [@bib187]). These antibody preparations may protect against *Str. mutans* by different mechanisms, such as inhibiting the formation of extracellular polysaccharides (glucan and fructan) and preventing the adherence of *Str. mutans* to salivary coated hydroxyapatite and aggregation of *Str. mutans* ([@bib134], [@bib136]).

Another approach is the use of mAbs against the cell surface antigen I/II (SAI/II) adhesion molecule of *Str. mutans* ([@bib131], [@bib148], [@bib147], [@bib146]). Human volunteers receiving a treatment consisting of oral chlorhexidine disinfection followed by repeated topical applications of anti-AgI/II mAb (Guy's 13) onto the teeth showed a lack of re-colonization by indigenous *Str. mutans* for up to 2 years ([@bib147], [@bib146]). Because the functional mAb was only detected on the teeth for only up to 3 days after application, it was speculated that the ecological niche vacated by *Str. mutans* was filled by other bacteria ([@bib146]). This mAb was subsequently re-engineered as a chimeric IgA/IgG Ab with a rabbit secretory component for expression in tobacco plants. The plant-derived SIgA/G (CaroRx Planet Biotechnology) was reported to be effective in passive immunization trials in humans ([@bib144], [@bib145]) although another study reported only a trend in reducing colonization by *Str. mutans* ([@bib258]). The product is currently undergoing phase II clinical trials in the United States.

An scFv was also derived from the mAb Guy's 13 and expressed in lactobacilli ([@bib121]). Administration of fresh lactobacilli expressing surface anchored scFv in drinking water reduced *Str. mutans* bacterial counts and caries development in rats ([@bib121], [@bib123]). Modified lactobacilli could prevent caries by different mechanisms such as blocking the SAI/II adhesion and aggregation of *Str. mutans* in combination with the production of inhibitory substances (e.g., bacteriocin) ([@bib123]). A VHH antibody fragment against the SAI/II adhesin (S36-VHH) also reduced the development of smooth surface caries in the desalivated rat caries model ([@bib122]).

### Porphyromonas gingivalis {#s0100}

*Porphyromonas gingivalis*, a gram-negative anaerobe present in subgingival plaque, was identified as a major etiologic agent of chronic periodontitis ([@bib154]). The factors by which *Po. gingivalis* might express its virulence include lipopolysaccharides, hemagglutinin, fimbriae, and the Arg-X-specific (Rgp) and Lys-X-specific (Kgp) cysteine proteinases (the gingipains) ([@bib6]).

Immunoglobulin Y against the *Po. gingivalis* 40-kD outer membrane protein and hemagglutinin (HagA) were found to inhibit aggregation and hemagglutination in vitro ([@bib80], [@bib236]). Egg yolk antibodies against *Po. gingivalis* gingipains decreased bacterial adhesion and hydrolytic activity in vitro ([@bib270]) and reduced levels of *Po. gingivalis* when applied to the teeth of periodontitis patients ([@bib269]).

The anti*-Po. gingivalis* mAb 61BG1.3 is reactive with the adhesion-associated epitope contained in the beta fragment of gingipain RgpA and has been shown to inhibit hemagglutination of human red blood cells by *Po. gingivalis* ([@bib21]). Topical application of the mAb in patients with periodontitis prevented recolonization with *Po. gingivalis* for up to 9 months ([@bib20]). Modified lactobacilli expressing scFv derived from 61BG1.3 on the cell surface were also shown to aggregate *Po. gingivalis* and inhibit its growth in vitro ([@bib153]).

### Candida albicans {#s0105}

Oropharyngeal candidiasis is mostly associated with *Candida albicans* and is a major cause of morbidity in immunocompromised patients such as HIV or organ- and bone marrow-transplanted patients ([@bib56], [@bib97]). The narrow range of antifungal agents, the toxicity of some of the drugs, and the emergence of resistant strains of *Can. albicans* highlight the need for new therapeutic approaches against invasive candidiasis ([@bib58]). Antibodies may have an important role by blocking the adhesion of *Can. albicans* to tissues, inhibiting germ tube formation, and promoting phagocytosis ([@bib28], [@bib43], [@bib51], [@bib259]).

Polyclonal IgY antibodies prepared against *Can. albicans* have been shown to prevent the growth, adherence to epithelial cells, and biofilm formation of *Can. albicans* in vitro ([@bib71], [@bib254]) and reduced oral candidiasis and systemic dissemination when administered orally to immunosuppressed mice ([@bib102]). Antibodies from cows immunized with whole *Candida* organisms and purified mannan prevented the adherence of *Can. albicans* to oral buccal cells in a dose-dependent manner ([@bib257]) and reduced *Candida* counts in saliva when administered orally to bone marrow-transplanted patients ([@bib242]).

Efungumab (Mycograb^®^) was developed as a human recombinant scFv antibody fragment against a heat shock protein (hsp90) for the treatment of invasive *Candida* infection in combination with amphotericin B ([@bib161], [@bib162], [@bib188]). Despite efficacy of the combination treatment in an animal model and a clinical trial, Mycograb^®^ did not receive licensure from the European Medicines Agency for clinical use owing to safety concerns mainly regarding autoaggregation of the compound. Novartis AG then discontinued the development of this antibody. Despite these issues, efungumab demonstrated an important proof of principle for the development of mAbs with antifungal activity.

Lung Pathogens {#s0110}
--------------

### Streptococcus pneumoniae and Haemophilus influenzae Type b {#s0115}

Almost all patients with primary antibody deficiency (PAD) have upper and lower respiratory tract bacterial infections, predominantly otitis media, sinusitis, and pneumonia. Life-threatening infections in PAD patients are caused mainly by encapsulated bacteria, especially *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib). Furthermore, in infants and young children, Hib causes bacteremia, pneumonia, and acute bacterial meningitis. In the past 60 years, several studies have demonstrated that replacement Ig therapy (IVIG and SCIG) is beneficial for PAD patients ([@bib13], [@bib41], [@bib70], [@bib263]) ([Table 2](#t0015){ref-type="table"}). Furthermore, a human hyperimmunoglobulin termed bacterial polysaccharide immune globulin (BPIG) was prepared from plasma of donors immunized with Hib, pneumococcal, and meningococcal capsular PS vaccines. This product, administered intramuscularly, was protective against Hib bacteremia and meningitis, and pneumococcal otitis in infants ([@bib210], [@bib222], [@bib223]).

The main virulence factor of *Str. pneumoniae* and *H. influenzae* is their polysaccharide (PS) capsule, which reflects the important role of antibodies in opsonization of encapsulated bacteria. One option is thus to develop mAbs that target the capsular polysaccharide of the serotypes causing most infection and to give the mAbs as a mixture. Intraperitoneal administration of mAbs to the capsular polysaccharide protects mice against a lethal systemic or intranasal challenge with *Str. pneumoniae* serotype III ([@bib40], [@bib60], [@bib61], [@bib239], [@bib256]). Some of these protective mAbs do not promote phagocytosis in vitro. Their efficacy may depend on their capacity to agglutinate and alter the expression of gene involved in quorum sensing, tricking the bacteria to kill each other (fratricide) ([@bib59], [@bib239], [@bib266]).

### Pseudomonas aeruginosa {#s0120}

The gram-negative bacterium *Ps. aeruginosa* is an opportunistic nosocomial pathogen in immunocompromised patients and the major cause of morbidity and mortality in cystic fibrosis patients ([@bib174]). Already intrinsically resistant to many antibiotics, reports of *Ps. aeruginosa* acquisition of multidrug resistance to late-generation antibiotics are common ([@bib110]).

Administration of polyclonal antibody preparations derived from healthy human donors immunized with *Ps. aeruginosa* (Ps-IVIG) was associated with both greater and prolonged improvement in pulmonary function in patients with moderate cystic fibrosis ([@bib47]). The potential of mAbs targeting virulence factors was demonstrated in an animal model of *Ps. aeruginosa* pneumonia using systemic or intratracheal administration of mAbs targeting *Ps. aeruginosa* O-antigen lipopolysaccharide (LPS), flagella, alginate, exopolysaccharide, and components of the type 3 secretion system (pcrV) ([@bib1], [@bib12], [@bib55], [@bib62], [@bib90], [@bib193], [@bib216]).

In phase IIa clinical trials, infusion of the mAbs panobacumab (Kenta Biotech, Switzerland) and KB001 (KaloBios Pharmaceuticals, Inc, US), targeting the O-antigen LPS and pcrV, respectively, support the use of passive immunization against *Ps. aeruginosa* pneumonia in humans ([@bib67], [@bib141]). Furthermore, a mouth rinse containing purified anti-*Ps. aeruginosa* IgY given twice daily on a continuous basis could significantly reduce or prevent *Ps. aeruginosa* colonization in patient with cystic fibrosis ([@bib180], [@bib181]). The IgY preparation (PsAer-IgY) has received an orphan drug designation by the European Medicines Agency (EMEA) and a phase III, double-blind, randomized, controlled trial is under way.

#### Influenza Type A {#s0125}

Influenza type A viruses are subdivided into subtypes based on the antigenic properties of the two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) ([@bib49]). The multiple clades and subclades of influenza viruses and high mutation rate during infection constitute a considerable problem for human vaccine development ([@bib228]).

Systemic administration of polyclonal antibodies against influenza virus has been shown to be protective in human and mouse models of infection ([@bib117], [@bib140], [@bib274]). Furthermore, a single intranasal administration of IgY or hyperimmune bovine colostrum (HBC) anti-H1N1 is both prophylactically and therapeutically protective against an intranasal challenge with influenza virus ([@bib178], [@bib179]). The HA protein is responsible for receptor binding to host cells and for viral entry and elicits the most robust neutralizing antibodies during vaccination or natural infection. Several groups reported that systemic or intranasal administration of mAbs against HA provides protection of mice against a lethal intranasal challenge with the virus ([@bib196], [@bib197], [@bib233], [@bib238], [@bib267]). Antigenic drift, caused by periodic amino acid changes on the globular head of hemagglutinin (HA), is one of the hallmarks of influenza A virus immune evasion and the synergistic action of two or more mAbs in combination may be required to prevent the generation of escape mutants ([@bib197], [@bib196]). An alternative is to develop antibodies targeting the conserved region of the HA and capable of recognizing and neutralizing a diverse number of influenza A virus subtypes ([@bib57], [@bib233]). A broadly neutralizing mAb (CR6261) was shown to bind to the highly conserved helical region in the HA stem/stalk domain ([@bib57], [@bib238]). The antibody, developed by Crucell (The Netherlands), is currently undergoing a phase I clinical trial fusing a single intravenous dose.

Camelidae heavy chain antibody fragments against H5N1 have also been developed and multivalent VHHs have been produced through genetic fusion of two or three neutralizing VHHs ([@bib96]). The bivalent H5N1-HA-specific VHH was at least 60-fold more effective at suppressing virus replication in the lungs than its monovalent counterpart and protected mice against a lethal H5N1 virus challenge both in a prophylactic and therapeutic setting ([@bib101]). Crosslinking of the spike subunit by multimerized VHHs may increase avidity, mediate agglutination of the viruses, or inhibit conformational changes of the viruses, thereby preventing fusion to host cell membranes ([@bib248]).

#### Respiratory Syncytial Virus {#s0130}

Respiratory syncytial virus is the leading viral pathogen responsible for lower respiratory tract infection (LRTI) requiring hospitalization in infants and young children worldwide. Respiratory syncytial virus has recently been found to have a high prevalence in the elderly and in immunocompromised adults, particularly bone marrow and lung transplant recipients, leading to considerable morbidity and mortality ([@bib100]). The two glycosylated surface proteins, F and G, are crucial for the infectivity and pathogenesis of the virus and elicit production of neutralizing antibodies by the host ([@bib78]). The lack of effective therapy and a vaccine against RSV infection has led to studies examining the effectiveness of passive immunity ([@bib198]).

Two RSV passive antibody preparations were originally licensed. Respiratory syncytial virus--IGIV is a hyperimmune polyclonal human IgG preparation derived from plasma donors with high RSV neutralizing antibody titers, approved in 1996 for use in infants and children younger than 24 months with chronic lung disease or a history of premature birth. Palivizumab (Synagis, MedImmune, Gaithersburg, MD) is a humanized IgG1 mAb directed against the antigenic site II of the F glycoprotein, and blocks virus fusion, most likely through inhibiting the conformational changes in the F protein required for this process ([@bib95]). Palivizumab is licensed for the reduction of severe lower respiratory tract RSV infection in high-risk infants and children. Both palivizumab and RSV-IGIV similarly decrease the incidence of RSV hospitalization (by 30--60%) and intensive care unit admission but RSV-IGIV results in more adverse effects and requires intravenous access ([@bib172]). Palivizumab might also be a viable option for prophylaxis against RSV in patients undergoing allogeneic stem cell transplantation, pre-engraftment, during graft-versus-host disease, and when treated with high-dose steroids ([@bib111]).

A VHH antibody fragment (VHH RSV-D3) directed against the antigenic site II of the F protein and competing with palivizumab has been isolated. Remarkably, linking two identical RSV-D3 VHH improved in vitro neutralization about 4000-fold ([@bib96]). A trivalent molecule consisting of three identical anti-RSV VHHs (ALX-0171, Ablynx) was also constructed and shown to be protective by intranasal instillation in the cotton rat model even 2 days after infection ([www.ablynx.com](http://www.ablynx.com){#interref3}). A phase I study in healthy volunteers indicated that ALX-0171 could be successfully administered via nebulization directly into the lung and induced no significant clinically relevant adverse events ([www.ablynx.com](http://www.ablynx.com){#interref4}).

Gastrointestinal Pathogens {#s0135}
--------------------------

### Helicobacter pylori {#s0140}

*Helicobacter pylori* infection is responsible for chronic gastritis and peptic ulcer disease and is associated with an increased risk of developing stomach cancer ([@bib230]). Although antimicrobial therapy is available, the cost of antibiotic therapy and the appearance of antibiotic resistance suggest that an effective alternative prevention strategy would be of great benefit, particularly in developing countries. The most prominent *H. pylori* virulence factors are the blood group antigen-binding adhesins (BabA, BabB, and BabC), the sialic acid-binding adhesin (SabA), the cytotoxin-associated antigen (CagA), the vacuolating cytotoxin (VacA), and urease, which is involved in gastric acid neutralization ([@bib11]). The delayed acquisition of *H. pylori* by Gambian infants corresponding to their mothers' levels of breast milk IgA specific for *H. pylori* suggests that oral administration of antibodies might be used to prevent or reduce infection by *H. pylori* ([@bib76], [@bib237]). Furthermore, mice given mouse mAbs against *Helicobacter* or virulence factor (urease) at the time of the initial challenge are protected from infection ([@bib18], [@bib48]) ([Table 3](#t0020){ref-type="table"}).

Antibodies from cows or chickens immunized with whole cell lysates or urease inhibit the adherence of *H. pylori* to the gastric mucosa and growth and urease activity in vitro ([@bib34], [@bib33], [@bib220], [@bib221]). Oral administration of these antibody preparations also reduces colonization by *H. pylori* and associated gastritis in a rodent model ([@bib34], [@bib33], [@bib152], [@bib182], [@bib220], [@bib221]). However, clinical studies on the effect of oral administration of colostrum antibodies and IgY antibodies against *H. pylori* in humans are rare and show contradictory results. Some studies thus showed a decrease in colonization and symptoms ([@bib5], [@bib33], [@bib234]) whereas other studies have shown no effect of colostrum-derived antibodies ([@bib34], [@bib33], [@bib54], [@bib185]) or only a moderate effect by anti-urease IgY ([@bib89], [@bib231]).

Few antibodies against *H. pylori* adhesins have been developed, although the latter have been identified and well characterized ([@bib9], [@bib104], [@bib151]). Recently, an scFv antibody fragment against BabA adhesin (Abba3) was isolated from a phage library derived from PBMC of *H. pylori* infected humans (Schmidt et al., in preparation). A complete human antibody derived from the scFv (Abba3-IgG) prevented the adherence of *H. pylori* to stomach sections.

#### Rotavirus {#s0145}

Rotavirus is the most important etiologic agent of severe diarrhea in young children, accounting for an estimated 500,000 deaths each year mainly in the developing world. The two licensed vaccines (Rotarix^™^ and Rotateq^™^) have reduced efficacy (39.3--61.2%) in developing countries in Africa and Asia ([@bib8], [@bib149]) compared with developed countries (\>85%) ([@bib208], [@bib252]). There is thus a need for alternative strategies to complement vaccination strategies in situations where efficacy of vaccination alone may not be sufficient ([@bib155]).

Studies in humans and mice suggest a role of secretory IgA and serum IgG antibodies in protection against rotavirus ([@bib46], [@bib105], [@bib250]). The outer capsid proteins VP7 and VP4 and the intermediate layer protein VP6 are likely to be the most important targets of the host neutralizing response ([@bib2], [@bib26], [@bib45], [@bib207]). Monoclonal Abs against VP4 inhibit infection by blocking attachment ([@bib206]), antibodies against VP7 inhibit decapsidation ([@bib7]), and VP6 antibodies inhibit genome transcription and viral transcription in vitro ([@bib63]).

Several studies have shown that passive immunization using hyperimmune polyclonal bovine colostrum or hyperimmunized chicken egg yolk Ig is protective in animal models and humans ([@bib50], [@bib82], [@bib190], [@bib212], [@bib211], [@bib213], [@bib257]). Novel approaches to the prevention and treatment of rotavirus-induced diarrhea are being developed to reduce the medical and economic burden in both developed and developing countries. One isolated VHH, named ARP1 (also referred to as 2B10 or VHH1), was shown to be broadly cross-reactive against different human rotavirus serotypes and provided protection in a mouse pup model of rotavirus infection ([@bib2], [@bib246]). Most important, oral administration of ARP1 was safe and effective in reducing severity of diarrhea in children in a phase II therapeutic clinical trial conducted in Bangladesh ([@bib280]).

Based on these studies, modified lactobacilli producing surface anchored VHH antibody fragments directed against rotavirus (ARP1) were constructed and shown to bind to rotavirus and to be protective against rotavirus-induced diarrhea in mouse pups ([@bib158], [@bib189], [@bib191]). The ARP1 fragment was also expressed at high level in rice (MucoRice-ARP1) using RNAi technology to suppress the production of major rice endogenous storage proteins ([@bib241]). MucoRice-ARP1 can be applied orally as rice powder or rice water by simply dissolving the MucoRice-ARP1 rice powder in water.

### Clostridium difficile {#s0150}

*Clostridium difficile* is a spore-forming, anaerobic bacterium that is a leading cause of antibiotic-associated diarrhea in hospitals and long-term care facilities ([@bib204]). The primary treatment regime of *Cl. difficile* infection is discontinuation of the instigating antibiotic and administration of vancomycin or metronidazole but 10--20% of patients experience relapse when antibiotic therapy is halted. Furthermore, the incidence and severity of *Cl. difficile* infection increased markedly over the past decade, in part because of the emergence of unusually virulent, antibiotic-resistant strains ([@bib204]).

The main strategy for passive immunization against *Cl. difficile* is based on antibodies neutralizing the two toxins responsible for the disruption of colonic epithelial tight junctions ([@bib10], [@bib42], [@bib156], [@bib209], [@bib261]). Two human mAbs directed against the receptor-binding domain of toxin A (mAb CDA1 or actoxumab) or toxin B (mAb CDB1, MDX-1388 or bezlotoxumab), have been shown to neutralize the cytotoxic effects of either and prevent *Cl. difficile*-induced mortality in a hamster model ([@bib10]). In a phase II human trial, a single infusion of these two mAbs as an adjunct to treatment with either vancomycin or metronidazole was highly successful in reducing the rate of recurrent infection ([@bib139]). The two mAbs licensed to Merck will be tested in a phase III study.

The toxins could conceivably be neutralized within the lower gastrointestinal tract, thereby preventing the critical first step in *Cl. difficile*-associated disease pathogenesis. Oral administration of chicken IgY and bovine antibody directed against toxin A and B was protective in the hamster model of infection ([@bib114], [@bib115], [@bib143], [@bib205]). Targeting other *Cl. difficile* virulence factors involved in adherence, such as the flagellar cap protein (FliD), may also be effective in preventing *Cl. difficile* infection ([@bib175]).

There have been limited reports on *Cl. difficile*-associated diarrhea therapy with orally delivered antibodies in humans ([@bib113], [@bib255]). Bovine antibody-enriched whey prepared from cow's milk directed against *Cl. difficile* toxins and whole cells was shown to prevent relapse after standard antibiotic therapy, while being safe and well tolerated ([@bib247], [@bib183], [@bib271]). The limited evidence in oral immunotherapy in clinical settings has likely been hampered by the high Ig dose requirements and the associated costs. As an alternative, neutralizing single-domain antibodies derived from llamas are currently being developed against toxins A and B ([@bib99]). Furthermore, *Lactobacillus* producing surface-anchored VHH fragment against toxin B delay the death of hamsters after a challenge with spores from a toxin A-deleted *Cl. difficile* strain (Andersen et al., submitted).

### Escherichia coli {#s0155}

Diarrheagenic *E. coli* has been classified into five well-described groups based on the distinct virulence characteristics clinical disease and phylogenetic profiles. Among them are enterohemorrhagic *E. coli* (EHEC) strains, which are associated with hemorrhagic colitis and hemolytic-uremic syndrome in humans; enteropathogenic *E. coli* (EPEC) strains, which cause diarrhea in children; and enterotoxigenic *E. coli* (ETEC) strains, which are associated with traveler's diarrhea and cause diarrhea and at least 300,000 deaths annually in preschool children in developing countries ([@bib24], [@bib25], [@bib232]). Whereas ETEC and EHEC are characterized by the production of distinct toxins, the hallmark phenotype of EPEC is the ability to produce an attaching and effacing (A/E) lesion. Many antibiotics have been used to treat EPEC and ETEC, but this treatment option is threatened by the rise in multiple antibiotic-resistant strains of the bacteria ([@bib91]).

The fact that secretory Igs in breast milk protect neonates and young infants against diarrhea is important for considering and testing passive immunotherapy to manage this infection ([@bib138]). Intraperitoneal injection of mAbs against Shiga toxin reduces systemic complications and prolongs survival in mice and gnotobiotic pigs intestinally infected with *E. coli* EHEC ([@bib120], [@bib173], [@bib219]). Oral administration of anti-Stx-2 IgY reduced the mortality of mice infected intestinally with EHEC O157:H7 ([@bib177]). In addition, Ig preparations from cows and chickens immunized against EPEC, ETEC, and EHEC are effective as prophylaxis against infections in farm animals ([@bib103], [@bib157], [@bib200]).

Supplemental bovine milk-derived antibody preparations in infant feeding formulas were successfully used to treat active EPEC disease in infants in one of the earliest controlled studies using antibodies ([@bib168]). In addition, a hyperimmune bovine milk antibody product with specific activity against purified colonization factor antigens (CFAs) protected volunteers challenged with ETEC ([@bib68]). On the contrary, oral administration of a bovine Ig milk concentrate (BIC) from cows hyperimmunized with ETEC and EPEC strains gave no significant therapeutic benefit in a randomized, placebo-controlled study in children with *E. coli*-induced diarrhea in Bangladesh ([@bib35]). This could be because of differences in the specificity of the antibody preparations. A better approach might thus be to generate antibodies specific for virulence factors.

Vaginal Tract {#s0160}
-------------

### Human Immunodeficiency Virus {#s0165}

According to estimates by the World Health Organization and the Joint United Nations Programme on HIV/Acquired Immunodeficiency Syndrome, more than 34 million people were living with HIV-1 infection at the end of 2011. Most HIV-1 transmission in women occurs on the mucosal surface of the endocervix, cervix, and vagina during unprotected vaginal intercourse ([@bib38], [@bib218]).

Despite the extraordinary genetic diversity of the virus, a few broadly neutralizing mAbs isolated from HIV-1-infected patients define conserved epitopes on the HIV Env ([@bib94], [@bib253], [@bib265]). The most extensively studied mAbs are 4E10 and 2F5, which recognize the membrane proximal external region (MPER) of gp41, 2G12 targeting the carbohydrate-specific epitope on the outer domain of gp120, and b12 directed against the CD4 binding site (CD4bs) on gp120 ([@bib253], [@bib265]). More potent mAbs have been isolated, such as VRC01, which targets the CD4bs and neutralized 91% of a 190-virus panel ([@bib264]).

Passive intravenous transfer of human neutralizing mAbs targeting gp120 (b12, 2G12) and gp40 (2F5, 4E10) provides dose-dependent protection to macaques vaginally challenged with the R5 strain of SHIV, which suggests that the antibodies may diffuse into the mucosal and submucosal layers ([@bib85], [@bib86], [@bib160], [@bib277], [@bib192]) ([Table 4](#t0025){ref-type="table"}). Furthermore, vaginally administered b12 and VRC01 protect against mucosal SHIV challenge in animal models, which suggests the use of antibodies as potential vaginal microbicides ([@bib249], [@bib251]). In humans, infusion with the neutralizing mAbs 4E10, 2F5, and 2G12 reduced viral rebound in HIV-1-infected individuals ([@bib245]). The same three mAbs are being assessed as a gel-formulated microbicide in a phase I clinical trial ([@bib278]). High concentrations of neutralizing mAbs show promise for microbicide formulations but they are prohibitively expensive to produce in the amounts required. Consequently, the anti-HIV-neutralizing antibodies 2F5 and 2G12 have been expressed at high levels in plants and excellent results have been obtained in terms of production and neutralizing activity ([@bib159], [@bib201], [@bib203]).

The humanized mAbs ibalizumab (formerly TNX-355 and Hu5A8, TaidMed Biologics, Taiwan) and PRO 140 (Progenics Pharmaceuticals, New York), targeting the receptors CD4 and CCR5, respectively, have shown promising results in early clinical trials when given as an intravenous infusion ([@bib23], [@bib106]). These antibodies might be used as a mixture with antibodies targeting the virus in a microbicide formulation.

Camelidae heavy chain antibody fragments reacting with the gp120 CD4bs, which neutralize a variety of HIV-1 strains, have also been isolated ([@bib66], [@bib107], [@bib166]). The leading VHH candidate (J3) neutralizes 94% of 65 HIV-1 strains of various clades, showing that broadly neutralizing VHHs can be generated against HIV-1 by immunization ([@bib166]). Camelidae heavy chain antibodies have a high potential for HIV-1 microbicide application because of their low production costs, high stability, favorable release from a vaginal ring device, and tissue penetration properties ([@bib75]).

Lactobacilli are found at about 10^8^ colony-forming units (CFU)/mL of vaginal fluid and 10--100 CFU per single vaginal epithelial cell, and have thus been suggested as vectors for delivery of antibody fragments and other microbicides in the genital tract ([@bib38], [@bib126], [@bib133]). Indeed, scFv against ICAM-1 produced by lactobacilli reduced transmission of cell-associated HIV both in vitro and in the Hu-PBL-SCID mouse model ([@bib38]).

Candida albicans {#s0170}
----------------

Chronic vulvovaginal candidiasis severely affects the quality of life for millions of women in the world and is frequently refractory to antifungal treatments ([@bib226]). Virulence factors of *Can. albicans* include mannoproteins that favor fungal adherence as well as aspartyl proteinase(s) (Sap) that have a crucial role in the acquisition of nutrients and invasion and destruction of the host tissue barrier ([@bib51]). Intravaginal administration of mAbs or human single-domain antibodies (VH or Vκ chain) recognizing the 65-kDa mannoprotein (MP65) or the secretory aspartyl proteinase-2 (SAP-2) of *Can. albicans* conferred protection against a vaginal challenge ([@bib28], [@bib52], [@bib51]). Monoclonal antibodies targeting β1,3-glucan, a major cell wall component, inhibited hyphal growth and adherence to human epithelial cells in vitro and conferred significant protection against *Can. albicans* in a vaginal rat model of *Can. albicans* infection ([@bib29], [@bib243], [@bib244]).

The development of anti-idiotypic antibodies with yeast killer toxin (KT) activity opens a new avenue for therapeutic application ([@bib32], [@bib150]). Monoclonal Abs and scFv fragments carrying the internal image of the active domain of a KT produced by *Pichia anomala* were elicited by idiotypic vaccination of rats with a KT-neutralizing mouse mAb KT4 ([@bib150], [@bib195]). Yeast killer toxin anti-idiotypic monoclonal (mAb K10) and scFv (scFv-H6) antibodies were able to exert a direct candidacidal activity in vitro and in the rat vaginitis model ([@bib150]). Furthermore, engineered *Streptococcus gordonii* strains producing scFv-H6 colonize the mucosal surfaces when inoculated intravaginally in rats and exert a therapeutic effect on *Can. albicans* vaginal infection ([@bib15]).

Passive Immunity: Toward the Future {#s0175}
===================================

Since Ehrlich's recognition of the potential of antibodies as therapeutic agents in the early twentieth century, antibodies have gained importance for the treatment of a variety of diseases. Today, passive antibody administration is used to treat and prevent diseases caused by hepatitis B virus, rabies virus, RSV, *Cl. tetani*, *Cl. botulinum*, vaccinia virus, echovirus, and enterovirus ([@bib31]). The administration of horse antitoxin remains the only specific therapy available for botulism. Antibodies can be administered as human or animal plasma or serum; as pooled human Ig for intravenous (IVIG), intramuscular (IMIG), and subcutaneous (SCIG) use; as high-titer human IVIG or IMIG from immunized or convalescing donors; or as mAb. In patients with PAD, prophylactic replacement therapy by SCIG or intravenous IMIG is the method of choice to prevent infections.

Antibody therapy against HIV, rotavirus, influenza, *Bacillus anthracis*, *Cryptococcus neoformans, Cl. difficile, Str. mutans, Ps. aeruginosa*, and *Can. albicans* are in clinical development. Antibodies against various other microorganisms including *H. pylori* and *E. coli* are under research development. Renewed interest in antibody-based therapies is the consequence of major advances in the technology of antibody production combined with the need for new therapeutic agents against emerging diseases (Ebola, severe acute respiratory syndrome, bird flu, West Nile virus, and bioterrorism agents) and new antibiotic-resistant microorganisms (*Staphylococcus aureus*, *E. coli*, Enterococci, and *Cl. difficile*). However, although antibodies have proven to be good antimicrobial agents, only one mAb, palivizumab, is licensed for an infectious disease (RSV infection). It is hoped that advances in genomics and proteomics will result in improved knowledge regarding the molecular mechanisms of pathogenicity. The possibility of generating fully human antibodies from transgenic, humanized mice, and perhaps in the near future transgenic humanized cows, as well as new developments in phage library technology will accelerate the development of antibody production. Furthermore, production of antibodies at lower cost using transgenic plants and transgenic cows as well as in situ delivery of antibody fragments by recombinant bacteria will lead to new applications of antibodies as therapeutics against infectious disease, such as mucosal delivery. Antibodies engineered in different formats and fused to other antimicrobials will result in increased potency and new molecular methods will render them non-immunogenic. All of these new developments will contribute to the realization of Erhlich's dream: magic bullets.
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[^1]: BIC, hyperimmune bovine immunoglobulin concentrate; HBC, hyperimmune bovine colostrum.

[^2]: ART, antiretroviral therapy.
